image: https://www.globalnewslines.com/uploads/2025/12/1767103008.jpg
$BFRG has published a white paper titled “AI in Bioinformatics: Turning Complex Data into Actionable Insights Using the Registered BullFrog Data Network”
* Leverage artificial intelligence and machine learning to drive critical drug discovery and development.
* Collaborations with leading research institutions including the Johns Hopkins Applied Physics Laboratory.
* Annual letter to shareholders published details progress points and commercial priorities for 2025 and potential catalysts for 2026.
* AI in Bioinformatics: Turning Complex Data into Actionable Insights whitepaper published.
*Publication details detail how BullFrog Data Networks Registered and bfLEAP Registered Technology address fundamental AI challenges in drug discovery and development.
* Expanded sales and marketing team to accelerate commercial implementation of clinical trial optimization solutions and BFRG technology.
* Expanded sales team to accelerate adoption of bfPREP products and the company's extensive clinical trial optimization solutions.
BullFrog AI Holdings, Inc: (Nasdaq: BFRG) leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaboration with leading research institutions, BFRG aims to use causal AI in conjunction with its proprietary bfLEAP Registered platform to analyze complex biological data, streamline therapeutic drug development, and reduce failure rates in clinical trials.
image: https://www.globalnewslines.com/uploads/2025/12/468f3b4ac818f4312e2564fbb87de261.jpg
Annual letter to shareholders highlights important progress in 2025 and outlines commercial priorities and potential catalysts for 2026
On December 30, BFRG released its annual letter to shareholders. The full text of this letter can be found at the following direct link: https://www.globenewswire.com/news-release/2025/12/30/3211355/0/en/BullFrog-AI-Publishes-Annual-Letter-to-Shareholders.html
The 2025 BFRG letter included the following points:
This year marked significant evolution for BullFrog AI, from platform development and initial validation to commercialization and enterprise adoption. At the core of BRFG's approach is the belief that artificial intelligence should enhance, not replace, human expertise. This enables scientists and clinicians to make better, faster, and more confident decisions across the drug discovery and development lifecycle through causal and explainable AI.
Commercial traction and growing reach
BFRG is currently in multiple advanced dialogues with global pharmaceutical organizations related to potential commercial transactions ranging from out-licensing to drug discovery research collaborations. Each of these potential relationships represents a meaningful “goal achievement” with a deal structure that includes upfront and milestone payments as well as long-term revenue sharing.
As for 2025, during the second quarter BFRG entered into a commercial partnership with Sygnature Discovery, one of the world's leading contract research organizations, which is expected to generate significant revenue through 2028. Following the official launch in late September, Sygnature's global business development team is currently actively introducing the BFRG Data Networks trademark to its biopharmaceutical customer base and expanding the company's commercial reach.
In parallel, BFRG expanded its internal sales and marketing efforts to directly support clinical trial optimization solutions. The team is increasingly leveraging proven platform successes, including validated oncology and neuroscience use cases, to drive deeper engagement across oncology, neuroscience and rare disease prospects, creating an enrichment cycle where proof of impact supports broader adoption discussions.
Enterprise-grade platform designed to support large-scale deployments
A key accomplishment this year is the continued evolution of BFRG technology into a modular, enterprise-grade solution stack designed to support broader commercial adoption. The launch of the BFRG Data Networks trademark and accompanying solution library represents meaningful progress in how large biopharmaceutical companies deploy our technology within their existing infrastructure and workflows.
Importantly, this architecture is designed to align with the way enterprise customers purchase and deploy technology, supporting iterative and scalable commercial relationships while maintaining the explainability and analytical rigor required for high-stakes scientific decision-making. As a result, the BFRG platform provides a foundation where data can be met with global pharmaceutical companies and further drive value as adoption grows across programs and use cases.
Scientific validation with real-world implications
Equally important, the partnership with Eleison Pharmaceuticals represents the first substantial real-world deployment of the BFRG AI platform in a late-stage oncology development program. This effort demonstrated BFRG's ability to operate within the rigor, scale, and constraints of advanced clinical development, providing actionable insights in an environment where data quality, interpretability, and reliability are critical.
The project was a huge success from both a scientific and operational perspective. Based on the value provided, Eleison is considering further collaboration with BFRG, reinforcing its belief that BFRG AI can serve as a long-term reliable partner for companies advancing late-stage pharmaceutical assets.
Separately, insights generated through this collaboration were featured in a co-authored abstract accepted for presentation at the 2026 ASCO Gastrointestinal Cancer Symposium, a highly respected oncology forum.
bfPREP Trademark: Turn bottlenecks into opportunities
One of the most strategically significant developments this year was the launch of bfPREP Trademark, a BFRG AI-powered data preparation and standardization module. Originally developed to support our work with Eleison, the bfPREP trademark addresses the persistent and costly challenge in life sciences and nearly every industry: transforming messy, fragmented, and unstructured data into AI-enabled structured datasets.
image: https://www.globalnewslines.com/uploads/2025/12/1a3e04550d9a1a243d7467c89ede879b.jpg
Capital discipline designed for asymmetrical appreciation
Throughout the year, BFRG maintained a disciplined approach to capital allocation while continuing to invest selectively in areas that support commercialization and platform scalability. BFRG AI operates with a lean cost structure and burns approximately $6.2 million annually, creating significant operating leverage as commercial opportunities transform. As a result, even a single meaningful partnership or revenue-generating initiative could significantly improve BFRG's financial profile, extend the runway of its business, and provide flexibility to reinvest for growth while limiting dilution. BFRG also introduced additional financing flexibilities, including a $10 million equity financing facility and an ATM to support execution as an opportunity.
White paper on AI in bioinformatics published
On November 18, BFRG announced the publication of a new white paper titled “AI in Bioinformatics: Turn complex data into actionable insights using BullFrog Data Networks Registered.”
The BFRG whitepaper identifies three major pitfalls in modern bioinformatics: the configuration data trap, the mirage of feature importance, and the overreach of generative AI. Each contributes to high failure rates in clinical development and billions of dollars in wasted R&D investments each year.
The BFRG bfLEAP Registered platform overcomes these challenges through causal inference modeling and probabilistic validation techniques originally developed at the Johns Hopkins Applied Physics Laboratory. Integrating these capabilities into BFRG Data Networks Registered provides reproducible insights across multimodal datasets including genomics, transcriptomics, proteomics, and clinical data, building the foundation for more confident target identification, biomarker discovery, and patient stratification.
This publication highlights the growing role of BFRGs in resolving one of the most pressing issues in drug development: the disconnect between the availability of large amounts of data and practical biological understanding. BFRG believes that the modular and scalable approach that combines the bfPREP trademark, bfLEAP registration, and BFRG Data Network registration is well-positioned to become the foundation of an AI-enabled research and development infrastructure for the world's pharmaceutical and biotech companies.
The complete BFRG whitepaper can be accessed via the direct link below. https://bullfrogai.com/resources/ai-in-bioinformatics-turning-complex-datainto-actionable-insights-with-bullfrog-datanetworks/.
Expands sales and marketing team to accelerate commercial implementation of clinical trial optimization solution and bfPREP trademark module
On September 30, BFRG announced the expansion of its internal sales organization to support accelerated commercialization of the company's clinical trial optimization products, including the recently launched bfPREP trademark module.
image: https://www.globalnewslines.com/uploads/2025/12/66c9724c1a73de33dea02ca6848d563f.jpg
BFRG's expansion of internal sales capabilities complements the company's recent commercial expansion, Sygnature Discovery, focused on selling BFRG Data Networks' trademarked target selection solutions to global biopharmaceutical customers. By strengthening its direct sales organization, BFRG is positioned to accelerate the adoption of clinical trial-focused platforms, including bfPREP, among pharmaceutical and biotech companies.
The BFRG bfPREP module was originally developed to support a collaboration with Eleison Pharmaceuticals and is purpose-built to handle the scale and complexity of diverse clinical trial data. bfPREP transforms raw information, from legacy records and siled datasets to unstructured documents, into standardized, analyzable formats at scale, delivering results in days.
BFRG's expanded sales team is working to accelerate the implementation of bfPREP and our extensive clinical trial optimization solutions. Once data is standardized through bfPREP, platforms such as bfLEAP Registered can be applied to reveal patient subgroups, inform trial design, and support more accurate implementation. By aligning these capabilities under a focused commercial strategy, BullFrog AI provides sponsors with an end-to-end approach to improving trial efficiency and outcomes.
For more information, please visit BFRG. https://bullfroguy.com [https://www.globenewswire.com/Tracker?data=Qj4e1lzhuBGeoFqYIJz4Vum8gXVsBNPlljRfNcde9gJCzPm2rf76VFd1hlDI-I7tBo5qMJWOBYRPKguYcub9bqTfWC6GE5eSs7gQASNgJAk-8fPpMNO9jsJy6q817pwS3N4GBD0Wc_FQHSHf3_lAw9zi8s9VBEr0Lw6-otxNLMCzpPJThdQmqBEE6QfGhCTN8fg3Plt26lgVXoqwOEYC1JAr3nZ-_EuAuqOi5DONunn9zv94A2eQPIB5za816Dj_yxAIqbwh2PL2ym-7ou4f0Q==]
Disclaimer: https://corporateads.com/disclaimer/
Disclosures found on the CorporateAds website
media contact
Company Name: BullFrog AI Holdings, Inc: (NASDAQ: BFRG)
Contact person: Vinh Xin, CEO
Email: Send email [http://www.universalpressrelease.com/?pr=milestone-progress-and-high-potential-in-ai-and-machine-learning-on-complex-biological-data-to-support-therapeutics-development-and-improve-clinical-trials-bullfrog-ai-holdings-inc-nasdaq-bfrg]
Phone: (240) 658-6710
Address:325 Ellington Boulevard Unit 317
City: Gaithersburg
Condition: MD 20878
Country: USA
Website: https://bullfroguy.com
Legal Disclaimer: The information contained on this page is provided by independent third-party content providers. GetNews does not warrant or accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are interested in this article or have a complaint or copyright issue related to this article and would like it removed, please contact us at retract@swscontact.com.
This release was published on openPR.
